Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852541 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL8773943 | 0.84 | LMNA (0.56) | LMNASMN1; SMN2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL9102086 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL8512366 | 0.80 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL5682572 | 0.80 | LMNA (0.56) | LMNASMN1; SMN2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL10875389 | 0.79 | LMNA (0.68) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL9413251 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1TSHRCYP1A2 | |
| SCHEMBL332859 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL22680970 | 0.78 | LMNA (0.68) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL9016334 | 0.77 | LMNA (0.53) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804161-A1 | CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES | NanoSystems L.L.C. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0760653-A1 | METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES | NanoSystems L.L.C. (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0756497-A1 | X-RAY CONTRAST COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE CLAYS | NYCOMED IMAGING AS (NO) | 1997-02-05 | — | — | EP | disclosed |
| WO-1996025182-A1 | PROCESS OF PREPARING X-RAY CONTRAST COMPOSITIONS CONTAINING NANOPARTICLES | NANOSYSTEMS L.L.C. (US) | 1996-08-22 | — | — | WO | disclosed |
| US-5543133-A | PREPARING PREMIX OF CONTRAST AGENT AND SURFACTANT; REDUCTION OF PARTICLE SIZE | NANOSYSTEMS L.L.C. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5518187-A | GRINDING PARTICLES OF DIAGNOSTIC IMAGING AGENT TO SUBMICRON SIZE WITH RIGID, SPHERICAL, POLYMER RESIN GRINDING MEDIA | NANO SYSTEMS L.L.C. (US) | 1996-05-21 | — | — | US | disclosed |
| WO-1995031973-A1 | CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES | NANOSYSTEMS L.L.C. (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995031974-A1 | METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES | NANOSYSTEMS L.L.C. (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995028969-A1 | X-RAY CONTRAST COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE CLAYS | NYCOMED IMAGING AS (NO) | 1995-11-02 | — | — | WO | disclosed |
| US-5451393-A | X-ray contrast compositions useful in medical imaging | EASTMAN KODAK COMPANY (US) | 1995-09-19 | — | — | US | disclosed |
| US-5318767-A | X-ray contrast compositions useful in medical imaging | STERLING WINTHROP INC. (US) | 1994-06-07 | — | — | US | disclosed |